ROLE OF LEUPRORELINE ACETATE DEPOT (LUCRIN DEPOT®) FORMULATIONS IN THE TREATMENT OF PROSTATE CANCER
https://doi.org/10.17650/1726-9776-2009-5-1-64-67
Abstract
Lucrin depot used to treat patients with prostate cancer has been investigated. The agent has been found to be highly effective, to causeadverse effects rarely, and to be well tolerated. The administration of leuproreline acetate yields the results comparable with those in the useof other luteining hormone-releasing hormone agonists and antagonists, bilateral orchiectomy, and estrogens.
About the Author
M. I. Volkova
Departament of Urology, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Аксель Е.М. Заболеваемость злокачественными новообразованиями мочевых и мужских половых органов в Рос-сии в 2003 г. Онкоурология 2005;(1):6—9.
2. Huggins C., Hodges C.V. Studies onprostatic cancer. I. The effect of castration,of estrogen and of androgen injection onserum phosphatases in metastatic carcino-ma ofthe prostate. Cancer Res 1941;1:293-7.
3. Barreca T., Martorana G., Franceschini R. et al. Suppression of testic-ular androgenesis by D-tryptophan-6-luteinizing hormone-releasing hormonedoes not affect TSH secretion in male sub-jects. Horm Res 1986;23(3):181-4.
4. Инструкция к препарату Люкрин-Депо, П №15554/01—170308.
5. Periti P., Mazzei T., Mini E. Clinicalpharmacokinetics of depot leuprorelin.Clin Pharmacokinet 2002;41(7):485—504.
6. Mazzei T., Mini E., Eandi M. et al.Pharmacokinetics, endocrine and antitu-mour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation. Drugs Exp Clin Res1989;15(8):373—87.
7. Kienle E., Lubben G. Efficacy and safe-ty of leuprorein depot for prostate cancer.Urol Int 1996;56(suppl 1):23—30.
8. Bischoff W., German Leuprorelin StudyGroup. 3,75 and 7,5 mg leuprorelin acetatedepot in the treatment of advanced prostatecancer: preliminary report. J Int Med Res1990;18(suppl 1):103—13.
9. Crawford E.D., Blumenstein B.A.,Goodman P.J. et al. Leuprolide with andwithout flutamide in advanced prostatecancer. Cancer 1990;66(5 Suppl):1039—44.
10. Sato K., Akakura S., Isaka H. et al.Intermittent androgen suppression forlocally advanced and metastatic prostatecancer: Preliminary report of a prospectivemulticenter study1. Urology2004;64(2):341—5.
11. Prezioso D., Lotti T., Polito M.,Montironi R., onbehalf of the NeoadjuvantStudy Group. Neoadjuvant hormone treat-ment with leuprolide acetate depot 3,75 mgand cyproterone acetate, before radicalprostatectomy: a randomized study. UrolInt 2004;72:189—95.
12. Leuprolide versus diethylstilbestrol formetastatic prostate cancer. The LeuprolideStudy Group. N Engl J Med1984;311:1281—6.
13. Heyns C.F., Simonin M.P., Grosgurin P. et al. For the South AfricanTriptorelin Study Group. Comparative effi-cacy of triptorelin pamoate and leuprolideacetate in men with advanced prostate can-cer. BJU Int 2003;92(3):226—31.
14. Аbbou C.C., Lucas C., Leblanc V.Tolerance and clinical and biologicalresponses during the first 6 months of treat-ment with 1-month sustained releaseLHRH agonists leuprolerin and triptolerinin patients with metastatic prostate cancer.Prog Urol 1997;7(6):984—95.
15. Seidenfeld J., Samson D.J., Hasselblad V. et al. Single-therapy andro-gen suppression in men with advancedprostate cancer: a systematic review andmeta-analysis. Ann Intern Med2000;132:566—77.
16. McLeod D., Zinner N., Gleason D. et al. for the Abarelix-Depot Study Group.Abarelix-depot (A-D) versus leuprolideacetate (L) for prostate cancer: results of amulti-institutional, randomized, phase IIIstudy in 271 patients. Proc Am Soc ClinOncol 2000;19:abstr 1306.
Review
For citations:
Volkova M.I. ROLE OF LEUPRORELINE ACETATE DEPOT (LUCRIN DEPOT®) FORMULATIONS IN THE TREATMENT OF PROSTATE CANCER. Cancer Urology. 2009;5(1):64-67. (In Russ.) https://doi.org/10.17650/1726-9776-2009-5-1-64-67
Views:
671
Email this article 